VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update
Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study
VolitionRx Announces $9 Million Private Placement
VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update
VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
Volition Extends Global Reach of its Clinical Trial Program
Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region
VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018
VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update
